{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R+II&page=6", "query": { "intervention": "M-M-R II", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 125, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R+II&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=M-M-R+II&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T11:58:06.458Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03704714", "title": "Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "B-Cell Non-Hodgkin Lymphoma", "CD20 Positive", "Diffuse Large B-Cell Lymphoma Unclassifiable", "Intravascular Large B-Cell Lymphoma", "Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-11-20", "completion_date": "2025-06-11", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 4, "location_summary": "Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" }, { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03704714" }, { "nct_id": "NCT00871117", "title": "Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tetanus", "Acellular Pertussis", "Diphtheria" ], "interventions": [ { "name": "GSK Biologicals'Kinrix®", "type": "BIOLOGICAL" }, { "name": "Merck and Company's MMRII", "type": "BIOLOGICAL" }, { "name": "Merck and Company's Varivax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "4 Years to 6 Years" }, "enrollment_count": 478, "start_date": "2009-03-31", "completion_date": "2010-06-15", "has_results": true, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 11, "location_summary": "Antioch, California • Daly City, California • Hayward, California + 7 more", "locations": [ { "city": "Antioch", "state": "California" }, { "city": "Daly City", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Roseville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00871117" }, { "nct_id": "NCT02481310", "title": "Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Burkitt Lymphoma", "B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma", "Diffuse Large B-Cell Lymphoma", "MYC Gene Mutation", "Plasmablastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2015-10-28", "completion_date": "2024-07", "has_results": true, "last_update_posted_date": "2022-02-21", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 5, "location_summary": "Chicago, Illinois • Medford, Massachusetts • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Medford", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02481310" }, { "nct_id": "NCT01544764", "title": "Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adolescent Health Services", "Immunization" ], "interventions": [ { "name": "Assessment , Feedback, Incentives, and eXchange Program", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 91, "start_date": "2011-04", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Raleigh, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01544764" }, { "nct_id": "NCT02600897", "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2016-03-24", "completion_date": "2021-12-15", "has_results": true, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 8, "location_summary": "Marietta, Georgia • Detroit, Michigan • Columbia, Missouri + 4 more", "locations": [ { "city": "Marietta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Columbia", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02600897" }, { "nct_id": "NCT04646239", "title": "Biomarkers of Trained Immunity Following MMR Vaccination", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Covid19" ], "interventions": [ { "name": "Heterologous stimuli", "type": "DIAGNOSTIC_TEST" }, { "name": "Neutralization assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2020-12-17", "completion_date": "2021-06-28", "has_results": false, "last_update_posted_date": "2021-11-26", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04646239" }, { "nct_id": "NCT06397768", "title": "Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "RSV Immunization" ], "interventions": [ { "name": "RSVt vaccine", "type": "BIOLOGICAL" }, { "name": "Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine", "type": "BIOLOGICAL" }, { "name": "Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis B vaccine", "type": "BIOLOGICAL" }, { "name": "Streptococcus pneumoniae vaccine", "type": "BIOLOGICAL" }, { "name": "Rotavirus vaccine", "type": "BIOLOGICAL" }, { "name": "Measles, mumps, and rubella vaccine", "type": "BIOLOGICAL" }, { "name": "Varicella virus vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "12 Months", "sex": "ALL", "summary": "6 Months to 12 Months" }, "enrollment_count": 2226, "start_date": "2024-05-13", "completion_date": "2025-09-18", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Grand Bay", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Bell Gardens", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06397768" }, { "nct_id": "NCT00263692", "title": "Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diphtheria", "Acellular Pertussis", "Tetanus" ], "interventions": [ { "name": "Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "4 Years to 6 Years" }, "enrollment_count": 401, "start_date": "2002-11", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2016-09-15", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 15, "location_summary": "Jonesboro, Arkansas • Fountain Valley, California • Oakland, California + 12 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00263692" }, { "nct_id": "NCT03172624", "title": "Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Salivary Gland Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2017-05-26", "completion_date": "2024-12-18", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03172624" }, { "nct_id": "NCT07222579", "title": "Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CD19 Positive", "Mixed Phenotype Acute Leukemia (MPAL)" ], "interventions": [ { "name": "Subcutaneous Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2026-01-15", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-19T11:58:06.458Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222579" } ] }